APO Research
Talk to an analyst

APO RESEARCH · REPORT

Urinary Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Urinary Drugs Market Outlook and Growth Opportunities 2026

21 December 2025193 pages

Choose your research edition.

Industry ResearchUrinary Drugs Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Urinary Drugs Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Urinary Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032186 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Urinary Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Urinary Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Urinary Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Urinary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Urinary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Urinary Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Urinary Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Urinary Drugs market include Sanofi S.A., Pfizer Inc., GlaxosmithKline Plc., Bayer AG, Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Astellas Pharma Inc. and Allergan Plc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Urinary Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Urinary Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Urinary Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Urinary Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Urinary Drugs Segment by Company

Sanofi S.A.

Pfizer Inc.

GlaxosmithKline Plc.

Bayer AG

Otsuka Pharmaceutical Co., Ltd.

Daiichi Sankyo Company Limited

Astellas Pharma Inc.

Allergan Plc.

Urinary Drugs Segment by Type

Oral

Injectables

Urinary Drugs Segment by Application

Clinic

Hospital

Home Care

Urinary Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Urinary Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Urinary Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Urinary Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Urinary Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urinary Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Urinary Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urinary Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Urinary Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Urinary Drugs industry.

Chapter 3: Detailed analysis of Urinary Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Urinary Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Urinary Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Urinary Drugs Industry Trends Table 2. Urinary Drugs Industry Drivers Table 3. Urinary Drugs Industry Opportunities and Challenges Table 4. Urinary Drugs Industry Restraints Table 5. Global Urinary Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Urinary Drugs Revenue Share by Company (2021-2026) Table 7. Global Urinary Drugs Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Urinary Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Urinary Drugs Average Price (US$/ton) of Company (2021-2026) Table 10. Global Urinary Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Urinary Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Urinary Drugs Company, Product Type & Application Table 13. Global Urinary Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Urinary Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of Injectables Table 19. Global Urinary Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 20. Global Urinary Drugs Sales Volume by Type (2021-2026) & (k tons) Table 21. Global Urinary Drugs Sales Volume by Type (2027-2032) & (k tons) Table 22. Global Urinary Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Urinary Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Urinary Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Urinary Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Urinary Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Urinary Drugs Sales Value Share by Type (2021-2026) Table 28. Global Urinary Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Clinic Table 30. Significant Companies of Hospital Table 31. Significant Companies of Home Care Table 32. Global Urinary Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 33. Global Urinary Drugs Sales Volume by Application (2021-2026) & (k tons) Table 34. Global Urinary Drugs Sales Volume by Application (2027-2032) & (k tons) Table 35. Global Urinary Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Urinary Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Urinary Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Urinary Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Urinary Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Urinary Drugs Sales Value Share by Application (2021-2026) Table 41. Global Urinary Drugs Sales Value Share by Application (2027-2032) Table 42. Global Urinary Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 43. Global Urinary Drugs Sales by Region (2021-2026) & (k tons) Table 44. Global Urinary Drugs Sales Market Share by Region (2021-2026) Table 45. Global Urinary Drugs Sales by Region (2027-2032) & (k tons) Table 46. Global Urinary Drugs Sales Market Share by Region (2027-2032) Table 47. Global Urinary Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Urinary Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Urinary Drugs Sales Value Share by Region (2021-2026) Table 50. Global Urinary Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Urinary Drugs Sales Value Share by Region (2027-2032) Table 52. Global Urinary Drugs Market Average Price (US$/ton) by Region (2021-2026) Table 53. Global Urinary Drugs Market Average Price (US$/ton) by Region (2027-2032) Table 54. Global Urinary Drugs Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 55. Global Urinary Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Urinary Drugs Sales by Country (2021-2026) & (k tons) Table 57. Global Urinary Drugs Sales Market Share by Country (2021-2026) Table 58. Global Urinary Drugs Sales by Country (2027-2032) & (k tons) Table 59. Global Urinary Drugs Sales Market Share by Country (2027-2032) Table 60. Global Urinary Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Urinary Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Urinary Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Urinary Drugs Sales Value Market Share by Country (2027-2032) Table 64. Sanofi S.A. Company Information Table 65. Sanofi S.A. Business Overview Table 66. Sanofi S.A. Urinary Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 67. Sanofi S.A. Urinary Drugs Product Portfolio Table 68. Sanofi S.A. Recent Development Table 69. Pfizer Inc. Company Information Table 70. Pfizer Inc. Business Overview Table 71. Pfizer Inc. Urinary Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Pfizer Inc. Urinary Drugs Product Portfolio Table 73. Pfizer Inc. Recent Development Table 74. GlaxosmithKline Plc. Company Information Table 75. GlaxosmithKline Plc. Business Overview Table 76. GlaxosmithKline Plc. Urinary Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. GlaxosmithKline Plc. Urinary Drugs Product Portfolio Table 78. GlaxosmithKline Plc. Recent Development Table 79. Bayer AG Company Information Table 80. Bayer AG Business Overview Table 81. Bayer AG Urinary Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. Bayer AG Urinary Drugs Product Portfolio Table 83. Bayer AG Recent Development Table 84. Otsuka Pharmaceutical Co., Ltd. Company Information Table 85. Otsuka Pharmaceutical Co., Ltd. Business Overview Table 86. Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Product Portfolio Table 88. Otsuka Pharmaceutical Co., Ltd. Recent Development Table 89. Daiichi Sankyo Company Limited Company Information Table 90. Daiichi Sankyo Company Limited Business Overview Table 91. Daiichi Sankyo Company Limited Urinary Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. Daiichi Sankyo Company Limited Urinary Drugs Product Portfolio Table 93. Daiichi Sankyo Company Limited Recent Development Table 94. Astellas Pharma Inc. Company Information Table 95. Astellas Pharma Inc. Business Overview Table 96. Astellas Pharma Inc. Urinary Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. Astellas Pharma Inc. Urinary Drugs Product Portfolio Table 98. Astellas Pharma Inc. Recent Development Table 99. Allergan Plc. Company Information Table 100. Allergan Plc. Business Overview Table 101. Allergan Plc. Urinary Drugs Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. Allergan Plc. Urinary Drugs Product Portfolio Table 103. Allergan Plc. Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Urinary Drugs Distributors List Table 107. Urinary Drugs Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Urinary Drugs Product Image Figure 2. Global Urinary Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Urinary Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Urinary Drugs Sales (2021-2032) & (k tons) Figure 5. Global Urinary Drugs Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Urinary Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. Injectables Image Figure 11. Global Urinary Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 12. Global Urinary Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Urinary Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Urinary Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Urinary Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Urinary Drugs Sales Value Share by Type (2021-2032) Figure 17. Clinic Image Figure 18. Hospital Image Figure 19. Home Care Image Figure 20. Global Urinary Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 21. Global Urinary Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Urinary Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Urinary Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Urinary Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Urinary Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Urinary Drugs Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 27. Global Urinary Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Urinary Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Urinary Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Urinary Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Urinary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Urinary Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Urinary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Urinary Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Urinary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Urinary Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Urinary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Urinary Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Urinary Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Urinary Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Urinary Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Urinary Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Urinary Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Urinary Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injectables
Applications
  • Clinic
  • Hospital
  • Home Care
Companies covered
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxosmithKline Plc.
  • Bayer AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Company Limited
  • Astellas Pharma Inc.
  • Allergan Plc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Urinary Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Urinary Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Urinary Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Urinary Drugs Market Dynamics
  1. 2.1 Urinary Drugs Industry Trends
  2. 2.2 Urinary Drugs Industry Drivers
  3. 2.3 Urinary Drugs Industry Opportunities and Challenges
  4. 2.4 Urinary Drugs Industry Restraints
3 Urinary Drugs Market by Company
  1. 3.1 Global Urinary Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Urinary Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Urinary Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Urinary Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Urinary Drugs Company Ranking (2024-2026)
  6. 3.6 Global Urinary Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Urinary Drugs Company Product Type and Application
  8. 3.8 Global Urinary Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Urinary Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Urinary Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Urinary Drugs Market by Type
  1. 4.1 Urinary Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injectables
  4. 4.2 Global Urinary Drugs Sales Volume by Type
  5. 4.2.1 Global Urinary Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Urinary Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Urinary Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Urinary Drugs Sales Value by Type
  9. 4.3.1 Global Urinary Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Urinary Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Urinary Drugs Sales Value Share by Type (2021-2032)
5 Urinary Drugs Market by Application
  1. 5.1 Urinary Drugs Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Home Care
  5. 5.2 Global Urinary Drugs Sales Volume by Application
  6. 5.2.1 Global Urinary Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Urinary Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Urinary Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Urinary Drugs Sales Value by Application
  10. 5.3.1 Global Urinary Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Urinary Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Urinary Drugs Sales Value Share by Application (2021-2032)
6 Urinary Drugs Regional Sales and Value Analysis
  1. 6.1 Global Urinary Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Urinary Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Urinary Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Urinary Drugs Sales by Region (2027-2032)
  5. 6.3 Global Urinary Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Urinary Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Urinary Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Urinary Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Urinary Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Urinary Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Urinary Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Urinary Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Urinary Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Urinary Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Urinary Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Urinary Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Urinary Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Urinary Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Urinary Drugs Sales Value Share by Country, 2025 VS 2032
7 Urinary Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Urinary Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Urinary Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Urinary Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Urinary Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Urinary Drugs Sales by Country (2027-2032)
  6. 7.4 Global Urinary Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Urinary Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Urinary Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Urinary Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Urinary Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Urinary Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Urinary Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Urinary Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Urinary Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Urinary Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Urinary Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Urinary Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Urinary Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Urinary Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Urinary Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Urinary Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Urinary Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Urinary Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Urinary Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Urinary Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Urinary Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Urinary Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Urinary Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Urinary Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Urinary Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Urinary Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Urinary Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Urinary Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Urinary Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Urinary Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Urinary Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Urinary Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Urinary Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Urinary Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi S.A.
  2. 8.1.1 Sanofi S.A. Company Information
  3. 8.1.2 Sanofi S.A. Business Overview
  4. 8.1.3 Sanofi S.A. Urinary Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi S.A. Urinary Drugs Product Portfolio
  6. 8.1.5 Sanofi S.A. Recent Developments
  7. 8.2 Pfizer Inc.
  8. 8.2.1 Pfizer Inc. Company Information
  9. 8.2.2 Pfizer Inc. Business Overview
  10. 8.2.3 Pfizer Inc. Urinary Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc. Urinary Drugs Product Portfolio
  12. 8.2.5 Pfizer Inc. Recent Developments
  13. 8.3 GlaxosmithKline Plc.
  14. 8.3.1 GlaxosmithKline Plc. Company Information
  15. 8.3.2 GlaxosmithKline Plc. Business Overview
  16. 8.3.3 GlaxosmithKline Plc. Urinary Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GlaxosmithKline Plc. Urinary Drugs Product Portfolio
  18. 8.3.5 GlaxosmithKline Plc. Recent Developments
  19. 8.4 Bayer AG
  20. 8.4.1 Bayer AG Company Information
  21. 8.4.2 Bayer AG Business Overview
  22. 8.4.3 Bayer AG Urinary Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bayer AG Urinary Drugs Product Portfolio
  24. 8.4.5 Bayer AG Recent Developments
  25. 8.5 Otsuka Pharmaceutical Co., Ltd.
  26. 8.5.1 Otsuka Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Otsuka Pharmaceutical Co., Ltd. Urinary Drugs Product Portfolio
  30. 8.5.5 Otsuka Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Daiichi Sankyo Company Limited
  32. 8.6.1 Daiichi Sankyo Company Limited Company Information
  33. 8.6.2 Daiichi Sankyo Company Limited Business Overview
  34. 8.6.3 Daiichi Sankyo Company Limited Urinary Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Daiichi Sankyo Company Limited Urinary Drugs Product Portfolio
  36. 8.6.5 Daiichi Sankyo Company Limited Recent Developments
  37. 8.7 Astellas Pharma Inc.
  38. 8.7.1 Astellas Pharma Inc. Company Information
  39. 8.7.2 Astellas Pharma Inc. Business Overview
  40. 8.7.3 Astellas Pharma Inc. Urinary Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Astellas Pharma Inc. Urinary Drugs Product Portfolio
  42. 8.7.5 Astellas Pharma Inc. Recent Developments
  43. 8.8 Allergan Plc.
  44. 8.8.1 Allergan Plc. Company Information
  45. 8.8.2 Allergan Plc. Business Overview
  46. 8.8.3 Allergan Plc. Urinary Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Allergan Plc. Urinary Drugs Product Portfolio
  48. 8.8.5 Allergan Plc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Urinary Drugs Value Chain Analysis
  2. 9.1.1 Urinary Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Urinary Drugs Sales Mode & Process
  6. 9.2 Urinary Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Urinary Drugs Distributors
  9. 9.2.3 Urinary Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst